The role of Factor Inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Wang, Enfeng ^a   Zhang, Chunyang ^b   Polavaram, Navatha ^c   Liu, Fengming ^d   Wu, Gang ^a,b   Schroeder, Mark A ^a   Lau, Julie S ^a   Mukhopadhyay, Debabrata ^a   Jiang, Shi Wen ^e,f   O'Neill, Brian Patrick ^a   Datta, Kaustubh ^c   Li, Jinping ^e,f  

^a MAYO CLINIC CANCER CENTER   (United States)

^b BAOTOU MEDICAL COLLEGE   (China)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Department of Research and Development Guangxi Medicinal Botanical Institute   (China)

^e MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Memorial Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CELL SURVIVAL; CHROMOSOME 10Q; CONTROLLED STUDY; DOWN REGULATION; FIH GENE; GENE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR GROWTH;

ANIMALS; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; E1A-ASSOCIATED P300 PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MIXED FUNCTION OXYGENASES; NEOPLASM TRANSPLANTATION; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899874531     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086102     Document Type: Article

References (58)

1. Vordermark D, Brown JM (2003) Evaluation of hypoxia-inducible factor-1alpha (HIF-1alpha) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies. International journal of radiation oncology, biology, physics 56:1184-93. (Pubitemid 36794054)
2. Mazure NM, Brahimi-Horn MC, Berta MA, Benizri E, Bilton RL, et al. (2004) HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochemical pharmacology 68:971-80. (Pubitemid 39094259)
3. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, et al. (2005) Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). The Journal of pathology 206:291-304. (Pubitemid 40903193)
4. Yeo EJ, Chun YS, Park JW (2004) New anticancer strategies targeting HIF-1. Biochemical pharmacology 68:1061-9.
5. Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, et al. (2006) Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer research 66:11991-7. (Pubitemid 46094213)
6. Brat DJ, Kaur B, Van Meir EG (2003) Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 8:d100-16. (Pubitemid 39069966)
7. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG (2004) Genetic and hypoxic regulation of angiogenesis in gliomas. Journal of neuro-oncology 70:229-43. (Pubitemid 39545734)
8. Evans SM, Jenkins KW, Jenkins WT, Dilling T, Judy KD, et al. (2008) Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors. Radiation research 170:677-90.
9. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, et al. (2001) A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensitymodulated radiation therapy. International journal of radiation oncology, biology, physics 49:1171-82. (Pubitemid 32184623)
10. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, et al.(2001) Malignant glioma: genetics and biology of a grave matter. Genes & development 15:1311-33. (Pubitemid 32524640)
11. Hill C, Hunter SB, Brat DJ (2003) Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Advances in anatomic pathology 10:212-7.
12. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America 92:5510-4.
13. Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, et al. (1997) Structural and functional analysis of hypoxia-inducible factor 1. Kidney international 51:553-5. (Pubitemid 27088174)
14. Luo G, Gu YZ, Jain S, Chan WK, Carr KM, et al.(1997) Molecular characterization of the murine Hif-1 alpha locus. Gene expression 6:287-99.
15. Gu YZ, Moran SM, Hogenesch JB, Wartman L Bradfield CA (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene expression 7:205-13. (Pubitemid 28527216)
16. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-5. (Pubitemid 29246458)
17. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (New York, NY 292:464-8.
18. Yu F, White SB, Zhao Q Lee FS (2001) Dynamic, site-specific interaction of hypoxia-inducible factor-1alpha with the von Hippel-Lindau tumor suppressor protein. Cancer research 61:4136-42. (Pubitemid 32720982)
19. Yu F, White SB, Zhao Q, Lee FS (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proceedings of the National Academy of Sciences of the United States of America 98:9630-5. (Pubitemid 32769354)
20. Kim W, Kaelin WG Jr (2003) The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Current opinion in genetics & development 13:55-60. (Pubitemid 36143928)
21. Safran M, Kaelin WG Jr (2003) HIF hydroxylation and the mammalian oxygen-sensing pathway. The Journal of clinical investigation 111:779-83. (Pubitemid 37074949)
22. Hirota K, Semenza GL (2005) Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochemical and biophysical research communications 338:610-6. (Pubitemid 41540610)
23. Kaelin WG (2005) Proline hydroxylation and gene expression. Annual review of biochemistry 74:115-28.
24. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54. (Pubitemid 32972036)
25. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, et al. (1996) An essential role for p300/CBP in the cellular response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 93:12969-73. (Pubitemid 26382753)
26. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, et al. (1998) Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. The EMBO journal 17:6573-86. (Pubitemid 28521792)
27. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer cell 1:237-46. (Pubitemid 41039148)
28. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, et al. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes & development 16:1466-71. (Pubitemid 34686328)
29. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, et al. (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. The Journal of biological chemistry 277:26351-5. (Pubitemid 34967127)
30. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, et al. (2002) Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proceedings of the National Academy of Sciences of the United States of America 99:5367-72. (Pubitemid 34411554)
31. Dann CE 3rd, Bruick RK, Deisenhofer J (2002) Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proceedings of the National Academy of Sciences of the United States of America 99:15351-6. (Pubitemid 35403938)
32. Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, Myllyharju J (2004) Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. The Journal of biological chemistry 279:9899-904. (Pubitemid 38372589)
33. Mahon PC, Hirota K, Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes & development 15:2675-86. (Pubitemid 32988878)
34. Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, et al. (2003) Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 alpha. The Journal of biological chemistry 278:1802-6. (Pubitemid 36801416)
35. Stolze IP, Tian YM, Appelhoff RJ, Turley H, Wykoff CC, et al. (2004) Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. The Journal of biological chemistry 279:42719-25. (Pubitemid 39372158)
36. Albarosa R, Colombo BM, Roz L, Magnani I, Pollo B, et al. (1996) Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. American journal of human genetics 58:1260-7. (Pubitemid 26153838)
37. Fults D, Pedone CA, Thompson GE, Uchiyama CM, Gumpper KL, et al. (1998) Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. International journal of oncology 12:905-10.
38. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP (1998) Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes, chromosomes & cancer 22:9-15. (Pubitemid 28217801)
39. Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, et al. (1993) Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Human genetics 92:169-74. (Pubitemid 23272283)
40. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (New York, NY 275:1943-7.
41. Sonoda Y, Murakami Y, Tominaga T, Kayama T, Yoshimoto T, et al. (1996) Deletion mapping of chromosome 10 in human glioma. Jpn J Cancer Res 87:363-7. (Pubitemid 26147849)
42. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature genetics 15:356-62. (Pubitemid 27147102)
43. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, et al. (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Laboratory investigation; a journal of technical methods and pathology 80:65-72.
44. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, et al. (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. Journal of neuropathology and experimental neurology 57:684-9. (Pubitemid 28335057)
45. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY 6:1-6.
46. Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, et al. (2006) Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res 12:2264-71.
47. Datta K, Mondal S, Sinha S, Li J, Wang E, et al. (2005) Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. Oncogene 24:7850-8. (Pubitemid 41715191)
48. Sinha S, Dutta S, Datta K, Ghosh AK, Mukhopadhyay D (2009) Von Hippel-Lindau gene product modulates TIS11B expression in renal cell carcinoma: impact on vascular endothelial growth factor expression in hypoxia. The Journal of biological chemistry 284:32610-8.
49. Misra S, Fu AA, Misra KD, Shergill UM, Leof EB, et al. (2010) Hypoxia-induced phenotypic switch of fibroblasts to myofibroblasts through a matrix metalloproteinase 2/tissue inhibitor of metalloproteinase-mediated pathway: implications for venous neointimal hyperplasia in hemodialysis access. J Vasc Interv Radiol 21:896-902.
50. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN (Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Current protocols in pharmacology/editorial board, S.J. Enna (editor-in-chief) ... [et al. Chapter 14:Unit 14 16.
51. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, et al. (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259-64. (Pubitemid 28220656)
52. Ohgaki H (2005) Genetic pathways to glioblastomas. Neuropathology 25:1-7.
53. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, et al. (2001) PTEN controls tumor-induced angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 98:4622-7. (Pubitemid 32295026)
54. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes & development 14:391-6. (Pubitemid 30131884)
55. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor1. Molecular and cellular biology 16:4604-13. (Pubitemid 26272112)
56. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, et al. (2002) Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. The Biochemical journal 367:571-5. (Pubitemid 35305697)
57. Linke S, Stojkoski C, Kewley RJ, Booker GW, Whitelaw ML, et al. (2004) Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factorinhibiting hypoxia-inducible factor. The Journal of biological chemistry 279:14391-7. (Pubitemid 38468981)
58. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, et al. (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncology 11:281-91.